KEGG   PATHWAY: hsa04510Help
Entry
hsa04510                    Pathway                                

Name
Focal adhesion - Homo sapiens (human)
Description
Cell-matrix adhesions play essential roles in important biological processes including cell motility, cell proliferation, cell differentiation, regulation of gene expression and cell survival. At the cell-extracellular matrix contact points, specialized structures are formed and termed focal adhesions, where bundles of actin filaments are anchored to transmembrane receptors of the integrin family through a multi-molecular complex of junctional plaque proteins. Some of the constituents of focal adhesions participate in the structural link between membrane receptors and the actin cytoskeleton, while others are signalling molecules, including different protein kinases and phosphatases, their substrates, and various adapter proteins. Integrin signaling is dependent upon the non-receptor tyrosine kinase activities of the FAK and src proteins as well as the adaptor protein functions of FAK, src and Shc to initiate downstream signaling events. These signalling events culminate in reorganization of the actin cytoskeleton; a prerequisite for changes in cell shape and motility, and gene expression. Similar morphological alterations and modulation of gene expression are initiated by the binding of growth factors to their respective receptors, emphasizing the considerable crosstalk between adhesion- and growth factor-mediated signalling.
Class
Cellular Processes; Cellular commiunity
BRITE hierarchy
Pathway map
Focal adhesion
hsa04510

All organismsOrtholog table
Disease
H00226  
Glanzmann thrombasthenia
H00539  
PTEN hamartoma tumor syndrome (PHTS)
H00567  
Caveolinopathies
H00576  
Pierson syndrome
H00577  
Syndromic X-linked mental retardation with epilepsy or seizures
H00579  
Hereditary angiopathy with nephropathy, aneurysms, and muscle cramps (HANAC)
H00581  
Alport syndrome
H00582  
Benign familial hematuria
H00585  
Epidermolysis bullosa, hemidesmosomal
H00586  
Epidermolysis bullosa, junctional
H00590  
Congenital muscular dystrophies (CMD/MDC)
H00593  
Limb-girdle muscular dystrophy (LGMD)
H00595  
Myofibrillar myopathies (MFM)
H00626  
Nephrotic syndrome and focal segmental glomerulosclerosis
H00801  
Familial thoracic aortic aneurysm and dissection (TAAD)
H00802  
Ehlers-Danlos syndrome (EDS)
H00805  
Vitreoretinal degeneration
H00813  
Laryngo onycho cutaneous syndrome
H00839  
Porencephaly
H00865  
Lethal congenital contractural syndrome (LCCS)
H00877  
Brain small vessel disease with Axenfeld-Rieger anomaly
H00894  
FG syndrome (FGS)
H00947  
Pilomatricoma
H01195  
VACTERL/VATER association
H01210  
Hypomagnesemia
H01255  
Juvenile-onset dystonia
H01260  
Glomerulopathy with fibronectin deposits (GFND)
H01274  
Growth delay due to insulin-like growth factor I resistance
H01276  
X-linked chronic idiopathic intestinal pseudo-obstruction
H01338  
Myosclerosis
H01340  
Bethlem myopathy
H01341  
Collagen VI myopathy
Drug
D01029  
Tirofiban hydrochloride (USAN)
D02778  
Abciximab (genetical recombination) (JAN)
D03065  
Becaplermin (USAN/INN)
D03257  
Trastuzumab (genetical recombination) (JAN)
D03297  
Mecasermin (genetical recombination) (JAN)
D03497  
Cilengitide (USAN/INN)
D03971  
Elarofiban (USAN)
D04659  
Lamifiban (USAN/INN)
D04660  
Lamifiban hydrochloride (USAN)
D04785  
Lotrafiban hydrochloride (USAN)
D04870  
Mecasermin rinfabate (USAN/INN)
D05267  
Orbofiban acetate (USAN)
D05446  
Pertuzumab (genetical recombination) (JAN)
D05772  
Roxifiban acetate (USAN)
D05819  
Semaxanib (USAN/INN)
D05834  
Sibrafiban (USAN/INN)
D06319  
Volociximab (USAN)
D06335  
Xemilofiban hydrochloride (USAN)
D06590  
Firategrast (USAN)
D06649  
Tadocizumab (USAN)
D06886  
Natalizumab (genetical recombination) (JAN)
D06888  
Eptifibatide (INN)
D08503  
Toceranib (USAN)
D08544  
Toceranib phosphate (USAN)
D08607  
Tirofiban (INN)
D08907  
Dovitinib lactate hydrate (JAN)
D09328  
Cixutumumab (USAN)
D09342  
Etaracizumab (USAN/INN)
D09345  
Figitumumab (USAN)
D09371  
Ramucirumab (genetical recombination) (JAN)
D09618  
Foretinib (USAN/INN)
D09631  
Intetumumab (USAN/INN)
D09635  
Linifanib (USAN/INN)
D09659  
Rilotumumab (USAN/INN)
D09683  
Tivozanib (USAN/INN)
D09746  
Dalotuzumab (USAN)
D09901  
Etrolizumab (USAN/INN)
D09908  
Ganitumab (USAN/INN)
D09919  
Lenvatinib (USAN/INN)
D09920  
Lenvatinib mesilate (JAN)
D09925  
Linsitinib (USAN/INN)
D09926  
Icrucumab (USAN/INN)
D09929  
Maraciclatide (USAN/INN)
D09939  
Olaratumab (USAN/INN)
D09941  
Onartuzumab (genetical recombination) (JAN)
D09945  
Pegdinetanib (USAN/INN)
D09980  
Trastuzumab emtansine (genetical recombination) (JAN)
D10018  
Necitumumab (USAN/INN)
D10028  
Valategrast hydrochloride (USAN)
D10056  
Robatumumab (USAN/INN)
D10123  
Ficlatuzumab (USAN)
D10465  
Golvatinib tartrate (USAN)
Other DBs
BSID: 
GO: 
Organism
Homo sapiens (human) [GN:hsa]
Gene
1277  
COL1A1; collagen, type I, alpha 1 [KO:K06236]
1278  
COL1A2; collagen, type I, alpha 2 [KO:K06236]
1280  
COL2A1; collagen, type II, alpha 1 [KO:K06236]
1281  
COL3A1; collagen, type III, alpha 1 [KO:K06236]
1289  
COL5A1; collagen, type V, alpha 1 [KO:K06236]
1290  
COL5A2; collagen, type V, alpha 2 [KO:K06236]
1301  
COL11A1; collagen, type XI, alpha 1 [KO:K06236]
1302  
COL11A2; collagen, type XI, alpha 2 [KO:K06236]
50509  
COL5A3; collagen, type V, alpha 3 [KO:K06236]
255631  
COL24A1; collagen, type XXIV, alpha 1 [KO:K06236]
85301  
COL27A1; collagen, type XXVII, alpha 1 [KO:K06236]
1284  
COL4A2; collagen, type IV, alpha 2 [KO:K06237]
1286  
COL4A4; collagen, type IV, alpha 4 [KO:K06237]
1288  
COL4A6; collagen, type IV, alpha 6 [KO:K06237]
1282  
COL4A1; collagen, type IV, alpha 1 [KO:K06237]
1287  
COL4A5; collagen, type IV, alpha 5 [KO:K06237]
1285  
COL4A3; collagen, type IV, alpha 3 (Goodpasture antigen) [KO:K06237]
1291  
COL6A1; collagen, type VI, alpha 1 [KO:K06238]
1292  
COL6A2; collagen, type VI, alpha 2 [KO:K06238]
1293  
COL6A3; collagen, type VI, alpha 3 [KO:K06238]
131873  
COL6A6; collagen, type VI, alpha 6 [KO:K06238]
256076  
COL6A5; collagen, type VI, alpha 5 [KO:K06238]
284217  
LAMA1; laminin, alpha 1 [KO:K05637]
3908  
LAMA2; laminin, alpha 2 [KO:K05637]
3909  
LAMA3; laminin, alpha 3 [KO:K06240]
3911  
LAMA5; laminin, alpha 5 [KO:K06240]
3910  
LAMA4; laminin, alpha 4 [KO:K06241]
3912  
LAMB1; laminin, beta 1 [KO:K05636]
3913  
LAMB2; laminin, beta 2 (laminin S) [KO:K06243]
3914  
LAMB3; laminin, beta 3 [KO:K06244]
22798  
LAMB4; laminin, beta 4 [KO:K06245]
3915  
LAMC1; laminin, gamma 1 (formerly LAMB2) [KO:K05635]
3918  
LAMC2; laminin, gamma 2 [KO:K06246]
10319  
LAMC3; laminin, gamma 3 [KO:K06247]
1101  
CHAD; chondroadherin [KO:K06248]
5649  
RELN; reelin [KO:K06249] [EC:3.4.21.-]
7057  
THBS1; thrombospondin 1 [KO:K16857]
1311  
COMP; cartilage oligomeric matrix protein [KO:K04659]
7058  
THBS2; thrombospondin 2 [KO:K04659]
7059  
THBS3; thrombospondin 3 [KO:K04659]
7060  
THBS4; thrombospondin 4 [KO:K04659]
2335  
FN1; fibronectin 1 [KO:K05717]
6696  
SPP1; secreted phosphoprotein 1 [KO:K06250]
7448  
VTN; vitronectin [KO:K06251]
3371  
TNC; tenascin C [KO:K06252]
63923  
TNN; tenascin N [KO:K06252]
7143  
TNR; tenascin R [KO:K06252]
7148  
TNXB; tenascin XB [KO:K06252]
7450  
VWF; von Willebrand factor [KO:K03900]
3381  
IBSP; integrin-binding sialoprotein [KO:K06253]
3672  
ITGA1; integrin, alpha 1 [KO:K06480]
3673  
ITGA2; integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) [KO:K06481]
3674  
ITGA2B; integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41) [KO:K06476]
3675  
ITGA3; integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor) [KO:K06482]
3676  
ITGA4; integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor) [KO:K06483]
3678  
ITGA5; integrin, alpha 5 (fibronectin receptor, alpha polypeptide) [KO:K06484]
3655  
ITGA6; integrin, alpha 6 [KO:K06485]
3679  
ITGA7; integrin, alpha 7 [KO:K06583]
8516  
ITGA8; integrin, alpha 8 [KO:K06584]
3680  
ITGA9; integrin, alpha 9 [KO:K06585]
8515  
ITGA10; integrin, alpha 10 [KO:K06586]
22801  
ITGA11; integrin, alpha 11 [KO:K06587]
3685  
ITGAV; integrin, alpha V [KO:K06487]
3688  
ITGB1; integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) [KO:K05719]
3690  
ITGB3; integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) [KO:K06493]
3691  
ITGB4; integrin, beta 4 [KO:K06525]
3693  
ITGB5; integrin, beta 5 [KO:K06588]
3694  
ITGB6; integrin, beta 6 [KO:K06589]
3695  
ITGB7; integrin, beta 7 [KO:K06590]
3696  
ITGB8; integrin, beta 8 [KO:K06591]
5154  
PDGFA; platelet-derived growth factor alpha polypeptide [KO:K04359]
5155  
PDGFB; platelet-derived growth factor beta polypeptide [KO:K17386]
56034  
PDGFC; platelet derived growth factor C [KO:K05450]
80310  
PDGFD; platelet derived growth factor D [KO:K05450]
1950  
EGF; epidermal growth factor [KO:K04357]
3479  
IGF1; insulin-like growth factor 1 (somatomedin C) [KO:K05459]
7422  
VEGFA; vascular endothelial growth factor A [KO:K05448]
7423  
VEGFB; vascular endothelial growth factor B [KO:K16858]
5228  
PGF; placental growth factor [KO:K16859]
7424  
VEGFC; vascular endothelial growth factor C [KO:K05449]
2277  
FIGF; c-fos induced growth factor (vascular endothelial growth factor D) [KO:K05449]
3082  
HGF; hepatocyte growth factor (hepapoietin A [KO:K05460]
5156  
PDGFRA; platelet-derived growth factor receptor, alpha polypeptide [KO:K04363] [EC:2.7.10.1]
5159  
PDGFRB; platelet-derived growth factor receptor, beta polypeptide [KO:K05089] [EC:2.7.10.1]
3480  
IGF1R; insulin-like growth factor 1 receptor [KO:K05087] [EC:2.7.10.1]
3791  
KDR; kinase insert domain receptor (a type III receptor tyrosine kinase) [KO:K05098] [EC:2.7.10.1]
1956  
EGFR; epidermal growth factor receptor [KO:K04361] [EC:2.7.10.1]
2321  
FLT1; fms-related tyrosine kinase 1 [KO:K05096] [EC:2.7.10.1]
2324  
FLT4; fms-related tyrosine kinase 4 [KO:K05097] [EC:2.7.10.1]
4233  
MET; MET proto-oncogene, receptor tyrosine kinase [KO:K05099] [EC:2.7.10.1]
2064  
ERBB2; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 [KO:K05083] [EC:2.7.10.1]
6714  
SRC; SRC proto-oncogene, non-receptor tyrosine kinase [KO:K05704] [EC:2.7.10.2]
2909  
ARHGAP35; Rho GTPase activating protein 35 [KO:K05732]
394  
ARHGAP5; Rho GTPase activating protein 5 [KO:K13709]
387  
RHOA; ras homolog family member A [KO:K04513]
1729  
DIAPH1; diaphanous-related formin 1 [KO:K05740]
6093  
ROCK1; Rho-associated, coiled-coil containing protein kinase 1 [KO:K04514] [EC:2.7.11.1]
9475  
ROCK2; Rho-associated, coiled-coil containing protein kinase 2 [KO:K17388] [EC:2.7.11.1]
4633  
MYL2; myosin, light chain 2, regulatory, cardiac, slow [KO:K10351]
4636  
MYL5; myosin, light chain 5, regulatory [KO:K12753]
58498  
MYL7; myosin, light chain 7, regulatory [KO:K12754]
10398  
MYL9; myosin, light chain 9, regulatory [KO:K12755]
93408  
MYL10; myosin, light chain 10, regulatory [KO:K12756]
103910  
MYL12B; myosin, light chain 12B, regulatory [KO:K12757]
10627  
MYL12A; myosin, light chain 12A, regulatory, non-sarcomeric [KO:K12757]
29895  
MYLPF; myosin light chain, phosphorylatable, fast skeletal muscle [KO:K12758]
5499  
PPP1CA; protein phosphatase 1, catalytic subunit, alpha isozyme [KO:K06269] [EC:3.1.3.16]
5500  
PPP1CB; protein phosphatase 1, catalytic subunit, beta isozyme [KO:K06269] [EC:3.1.3.16]
5501  
PPP1CC; protein phosphatase 1, catalytic subunit, gamma isozyme [KO:K06269] [EC:3.1.3.16]
4659  
PPP1R12A; protein phosphatase 1, regulatory subunit 12A [KO:K06270]
4660  
PPP1R12B; protein phosphatase 1, regulatory subunit 12B [KO:K12329]
54776  
PPP1R12C; protein phosphatase 1, regulatory subunit 12C [KO:K17457]
4638  
MYLK; myosin light chain kinase [KO:K00907] [EC:2.7.11.18]
85366  
MYLK2; myosin light chain kinase 2 [KO:K00907] [EC:2.7.11.18]
91807  
MYLK3; myosin light chain kinase 3 [KO:K00907] [EC:2.7.11.18]
340156  
MYLK4; myosin light chain kinase family, member 4 [KO:K00907] [EC:2.7.11.18]
60  
ACTB; actin, beta [KO:K05692]
71  
ACTG1; actin, gamma 1 [KO:K05692]
5923  
RASGRF1; Ras protein-specific guanine nucleotide-releasing factor 1 [KO:K04349]
824  
CAPN2; calpain 2, (m/II) large subunit [KO:K03853] [EC:3.4.22.53]
87  
ACTN1; actinin, alpha 1 [KO:K05699]
88  
ACTN2; actinin, alpha 2 [KO:K05699]
89  
ACTN3; actinin, alpha 3 [KO:K05699]
81  
ACTN4; actinin, alpha 4 [KO:K05699]
7094  
TLN1; talin 1 [KO:K06271]
83660  
TLN2; talin 2 [KO:K06271]
2316  
FLNA; filamin A, alpha [KO:K04437]
2318  
FLNC; filamin C, gamma [KO:K04437]
2317  
FLNB; filamin B, beta [KO:K04437]
5829  
PXN; paxillin [KO:K05760]
3611  
ILK; integrin-linked kinase [KO:K06272] [EC:2.7.11.1]
7791  
ZYX; zyxin [KO:K06273]
7408  
VASP; vasodilator-stimulated phosphoprotein [KO:K06274]
7414  
VCL; vinculin [KO:K05700]
29780  
PARVB; parvin, beta [KO:K06275]
55742  
PARVA; parvin, alpha [KO:K06275]
64098  
PARVG; parvin, gamma [KO:K06275]
5170  
PDPK1; 3-phosphoinositide dependent protein kinase 1 [KO:K06276] [EC:2.7.11.1]
207  
AKT1; v-akt murine thymoma viral oncogene homolog 1 [KO:K04456] [EC:2.7.11.1]
208  
AKT2; v-akt murine thymoma viral oncogene homolog 2 [KO:K04456] [EC:2.7.11.1]
10000  
AKT3; v-akt murine thymoma viral oncogene homolog 3 [KO:K04456] [EC:2.7.11.1]
2932  
GSK3B; glycogen synthase kinase 3 beta [KO:K03083] [EC:2.7.11.26]
1499  
CTNNB1; catenin (cadherin-associated protein), beta 1, 88kDa [KO:K02105]
5578  
PRKCA; protein kinase C, alpha [KO:K02677] [EC:2.7.11.13]
5579  
PRKCB; protein kinase C, beta [KO:K02677] [EC:2.7.11.13]
5582  
PRKCG; protein kinase C, gamma [KO:K02677] [EC:2.7.11.13]
5747  
PTK2; protein tyrosine kinase 2 [KO:K05725] [EC:2.7.10.2]
5290  
PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha [KO:K00922] [EC:2.7.1.153]
5293  
PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta [KO:K00922] [EC:2.7.1.153]
5291  
PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta [KO:K00922] [EC:2.7.1.153]
5294  
PIK3CG; phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma [KO:K00922] [EC:2.7.1.153]
5295  
PIK3R1; phosphoinositide-3-kinase, regulatory subunit 1 (alpha) [KO:K02649]
23533  
PIK3R5; phosphoinositide-3-kinase, regulatory subunit 5 [KO:K02649]
5296  
PIK3R2; phosphoinositide-3-kinase, regulatory subunit 2 (beta) [KO:K02649]
8503  
PIK3R3; phosphoinositide-3-kinase, regulatory subunit 3 (gamma) [KO:K02649]
5728  
PTEN; phosphatase and tensin homolog [KO:K01110] [EC:3.1.3.67 3.1.3.48 3.1.3.16]
10451  
VAV3; vav 3 guanine nucleotide exchange factor [KO:K05730]
7409  
VAV1; vav 1 guanine nucleotide exchange factor [KO:K05730]
7410  
VAV2; vav 2 guanine nucleotide exchange factor [KO:K05730]
5879  
RAC1; ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1) [KO:K04392]
5880  
RAC2; ras-related C3 botulinum toxin substrate 2 (rho family, small GTP binding protein Rac2) [KO:K07860]
5881  
RAC3; ras-related C3 botulinum toxin substrate 3 (rho family, small GTP binding protein Rac3) [KO:K07861]
5058  
PAK1; p21 protein (Cdc42/Rac)-activated kinase 1 [KO:K04409] [EC:2.7.11.1]
5062  
PAK2; p21 protein (Cdc42/Rac)-activated kinase 2 [KO:K04410] [EC:2.7.11.1]
5063  
PAK3; p21 protein (Cdc42/Rac)-activated kinase 3 [KO:K05733] [EC:2.7.11.1]
10298  
PAK4; p21 protein (Cdc42/Rac)-activated kinase 4 [KO:K05734] [EC:2.7.11.1]
56924  
PAK6; p21 protein (Cdc42/Rac)-activated kinase 6 [KO:K05735] [EC:2.7.11.1]
57144  
PAK7; p21 protein (Cdc42/Rac)-activated kinase 7 [KO:K05736] [EC:2.7.11.1]
998  
CDC42; cell division cycle 42 [KO:K04393]
9564  
BCAR1; breast cancer anti-estrogen resistance 1 [KO:K05726]
1398  
CRK; v-crk avian sarcoma virus CT10 oncogene homolog [KO:K04438]
1399  
CRKL; v-crk avian sarcoma virus CT10 oncogene homolog-like [KO:K04438]
1793  
DOCK1; dedicator of cytokinesis 1 [KO:K13708]
2889  
RAPGEF1; Rap guanine nucleotide exchange factor (GEF) 1 [KO:K06277]
5906  
RAP1A; RAP1A, member of RAS oncogene family [KO:K04353]
5908  
RAP1B; RAP1B, member of RAS oncogene family [KO:K07836]
5599  
MAPK8; mitogen-activated protein kinase 8 [KO:K04440] [EC:2.7.11.24]
5602  
MAPK10; mitogen-activated protein kinase 10 [KO:K04440] [EC:2.7.11.24]
5601  
MAPK9; mitogen-activated protein kinase 9 [KO:K04440] [EC:2.7.11.24]
3725  
JUN; jun proto-oncogene [KO:K04448]
673  
BRAF; B-Raf proto-oncogene, serine/threonine kinase [KO:K04365] [EC:2.7.11.1]
857  
CAV1; caveolin 1, caveolae protein, 22kDa [KO:K06278]
858  
CAV2; caveolin 2 [KO:K12958]
859  
CAV3; caveolin 3 [KO:K12959]
2534  
FYN; FYN proto-oncogene, Src family tyrosine kinase [KO:K05703] [EC:2.7.10.2]
6464  
SHC1; SHC (Src homology 2 domain containing) transforming protein 1 [KO:K06279]
25759  
SHC2; SHC (Src homology 2 domain containing) transforming protein 2 [KO:K17447]
53358  
SHC3; SHC (Src homology 2 domain containing) transforming protein 3 [KO:K17448]
399694  
SHC4; SHC (Src homology 2 domain containing) family, member 4 [KO:K17449]
2885  
GRB2; growth factor receptor-bound protein 2 [KO:K04364]
6654  
SOS1; son of sevenless homolog 1 (Drosophila) [KO:K03099]
6655  
SOS2; son of sevenless homolog 2 (Drosophila) [KO:K03099]
3265  
HRAS; Harvey rat sarcoma viral oncogene homolog [KO:K02833]
5894  
RAF1; Raf-1 proto-oncogene, serine/threonine kinase [KO:K04366] [EC:2.7.11.1]
5604  
MAP2K1; mitogen-activated protein kinase kinase 1 [KO:K04368] [EC:2.7.12.2]
5594  
MAPK1; mitogen-activated protein kinase 1 [KO:K04371] [EC:2.7.11.24]
5595  
MAPK3; mitogen-activated protein kinase 3 [KO:K04371] [EC:2.7.11.24]
2002  
ELK1; ELK1, member of ETS oncogene family [KO:K04375]
595  
CCND1; cyclin D1 [KO:K04503]
894  
CCND2; cyclin D2 [KO:K10151]
896  
CCND3; cyclin D3 [KO:K10152]
329  
BIRC2; baculoviral IAP repeat containing 2 [KO:K16060]
330  
BIRC3; baculoviral IAP repeat containing 3 [KO:K16060]
331  
XIAP; X-linked inhibitor of apoptosis [KO:K04725]
572  
BAD; BCL2-associated agonist of cell death [KO:K02158]
596  
BCL2; B-cell CLL/lymphoma 2 [KO:K02161]
23396  
PIP5K1C; phosphatidylinositol-4-phosphate 5-kinase, type I, gamma [KO:K00889] [EC:2.7.1.68]
Compound
C04637  
1-Phosphatidyl-D-myo-inositol 4,5-bisphosphate
C05981  
Phosphatidylinositol-3,4,5-trisphosphate
Reference
  Authors
Berman AE, Kozlova NI, Morozevich GE.
  Title
Integrins: structure and signaling.
  Journal
Biochemistry (Mosc) 68:1284-99 (2003)
Reference
  Authors
Lee JW, Juliano R.
  Title
Mitogenic signal transduction by integrin- and growth factor receptor-mediated pathways.
  Journal
Mol Cells 17:188-202 (2004)
Reference
  Authors
Danen EH, Yamada KM.
  Title
Fibronectin, integrins, and growth control.
  Journal
J Cell Physiol 189:1-13 (2001)
Reference
  Authors
Guo W, Giancotti FG.
  Title
Integrin signalling during tumour progression.
  Journal
Nat Rev Mol Cell Biol 5:816-26 (2004)
Reference
  Authors
Petit V, Thiery JP.
  Title
Focal adhesions: structure and dynamics.
  Journal
Biol Cell 92:477-94 (2000)
Reference
  Authors
Stupack DG, Cheresh DA.
  Title
Get a ligand, get a life: integrins, signaling and cell survival.
  Journal
J Cell Sci 115:3729-38 (2002)
Reference
  Authors
Parsons JT.
  Title
Focal adhesion kinase: the first ten years.
  Journal
J Cell Sci 116:1409-16 (2003)
Reference
  Authors
Mitra SK, Hanson DA, Schlaepfer DD.
  Title
Focal adhesion kinase: in command and control of cell motility.
  Journal
Nat Rev Mol Cell Biol 6:56-68 (2005)
Reference
  Authors
Comoglio PM, Boccaccio C, Trusolino L.
  Title
Interactions between growth factor receptors and adhesion molecules: breaking the rules.
  Journal
Curr Opin Cell Biol 15:565-71 (2003)
Reference
  Authors
Schlaepfer DD, Mitra SK.
  Title
Multiple connections link FAK to cell motility and invasion.
  Journal
Curr Opin Genet Dev 14:92-101 (2004)
Reference
  Authors
Burridge K, Wennerberg K.
  Title
Rho and Rac take center stage.
  Journal
Cell 116:167-79 (2004)
Reference
  Authors
Schmitz AA, Govek EE, Bottner B, Van Aelst L.
  Title
Rho GTPases: signaling, migration, and invasion.
  Journal
Exp Cell Res 261:1-12 (2000)
Reference
  Authors
Vanhaesebroeck B, Alessi DR.
  Title
The PI3K-PDK1 connection: more than just a road to PKB.
  Journal
Biochem J 346 Pt 3:561-76 (2000)
Reference
  Authors
Nicholson KM, Anderson NG.
  Title
The protein kinase B/Akt signalling pathway in human malignancy.
  Journal
Cell Signal 14:381-95 (2002)
Reference
  Authors
Oloumi A, McPhee T, Dedhar S.
  Title
Regulation of E-cadherin expression and beta-catenin/Tcf transcriptional activity by the integrin-linked kinase.
  Journal
Biochim Biophys Acta 1691:1-15 (2004)
Reference
  Authors
Turner CE.
  Title
Paxillin and focal adhesion signalling.
  Journal
Nat Cell Biol 2:E231-6 (2000)
Reference
  Authors
Hlobilkova A, Knillova J, Bartek J, Lukas J, Kolar Z.
  Title
The mechanism of action of the tumour suppressor gene PTEN.
  Journal
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 147:19-25 (2003)
KO pathway
 

DBGET integrated database retrieval system